China AI chip hopeful Enflame nears IPO with fast revenue growth, heavy losses, and Tencent risk

Enflame’s rush to the STAR Market reveals structural fragility beneath China’s 'domestic substitution' narrative in AI chips. Technically, reliance on TSMC’s 7nm without proprietary IP cores creates upstream exposure to export controls and downstream incompatibility with NVIDIA’s CUDA ecosystem—a performance island. Compliance-wise, a potential BIS UVL listing could sever advanced packaging partnerships, inflating yield costs by over 20%. Competitively, rivals like Cambricon or Biren may flood the market with discounted chips to capture Tencent-linked deals, trapping Enflame in a client-dependency–margin erosion loop. Within 18 months, without carving defensible verticals in large-model inference, its IPO valuation will deflate rapidly—as investor patience shifts from storytelling to cash-flow validation.